Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma

Targeted Oncology

Volumn 11, Issue 2, 2016, Pages 255-262

  Hoy, Sheridan M ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CARFILZOMIB; DEXAMETHASONE; LENALIDOMIDE; OLIGOPEPTIDE;

ACUTE KIDNEY FAILURE; ADVERSE OUTCOME; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER RECURRENCE; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; DYSPNEA; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LEUKOPENIA; LUNG EMBOLISM; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; STEADY STATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR RECURRENCE;

HUMANS; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; OLIGOPEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84961163929     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-016-0428-7     Document Type: Article

References (26)

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma. 3.2016. 2016. http://www.nccn.org/. Accessed 5 Feb 2016.
2. Usmani SZ, Rodriguez-Otero P, Bhutani M, et al. Defining and treating high-risk multiple myeloma. Leukemia. 2015;29(11):2119–25.
3. Dimopoulos MA, Richardson PG, Moreau P, et al. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015;12(1):42–54.
4. Onynx Pharmaceuticals Inc. KYPROLIS® (carfilzomib) for injection, for intravenous use: US prescribing information. 2016. http://www.fda.gov/drugsatfda. Accessed 5 Feb 2016.
5. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 2011;10(11):2034–42.
6. Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110(9):3281–90.
7. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67(13):6383–91.
8. Amgen Europe B.V. Kyprolis (carfilzomib) 60 mg powder for solution for infusion: EU summary of product characteristics. 2015. http://www.ema.europa.eu/ema/. Accessed 5 Feb 2016.
9. Parlati F, Lee SJ, Aujay M, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood. 2009;114(16):3439–47.
10. Alsina M, Trudel S, Furman RR, et al. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res. 2012;18(17):4830–40.
11. Niesvizky R, Martin 3rd TG, Bensinger WI, et al. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res. 2013;19(8):2248–56.
12. Wang M, Martin T, Bensinger W, et al. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood. 2013;122(18):3122–8.
13. Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120(9):1801–9.
14. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–52. plus supplementary appendix.
15. Yang G, Gao M, Zhang Y, et al. Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I. Oncotarget. 2015;6(29):26982–94.
16. Hu B, Chen Y, Usmani SZ, et al. Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. PLoS ONE. 2013;8(9): e74191.
17. Badros AZ, Vij R, Martin T, et al. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013;27(8):1707–14.
18. European Medicines Agency. Kyprolis (carfilzomib): assessment report. 2015. http://www.ema.europa.eu/ema/. Accessed 5 Feb 2016.
19. Dimopoulos MA, Stewart AK, Rajkumar SV, et al. Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391) [abstract no. 8525 plus poster]. J Clin Oncol. 2015;33(Suppl).
20. Stewart AK, Dimopoulos MA, Masszi T, et al. Superior health-related quality of life with carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma (MM): results from the ASPIRE trial. Clin Lymphoma Myeloma Leuk. 2015;15 Suppl 3: e76.
21. Moreau P, San Miguel J, Ludwig H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi133-7.
22. Rael M, Benedict A, Ishak J, et al. Indirect comparisons to assess the relative efficacy of carfilzomib + lenalidomide + dexamethasone versus panobinostat + bortezomib + dexamethasone and bortezomib + dexamethasone: a matching adjusted indirect comparison [abstract]. Blood. 2015;126(23):5622.
23. Rael M, Benedict A, Ishak J, et al. Indirect comparison to assess the relative efficacy of carfilzomib + lenalidomide + dexamethasone versus bortezomib + thalidomide + dexamethasone: a matching adjusted indirect comparison [abstract]. Blood. 2015;126(23):5624.
24. US National Institutes of Health. ClinicalTrials.gov. 2016. http://www.clinicaltrials.gov. Accessed 5 Feb 2016.
25. Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.
26. Amgen. Amgen submits application in Europe to expand indication of Kyprolis® (carfilzomib) for the treatment of relapsed multiple myeloma [media release]. 2015. http://wwwext.amgen.com/media/.